<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03109392</url>
  </required_header>
  <id_info>
    <org_study_id>Pulm.Med/2017/001</org_study_id>
    <nct_id>NCT03109392</nct_id>
  </id_info>
  <brief_title>A Randomized Trial of 4% Nebulized Lignocaine vs. 10% Lignocaine Spray in Patients Undergoing Flexible Bronchoscopy</brief_title>
  <official_title>A Randomized-controlled Trial to Compare the Effectiveness of 4% Nebulized Lignocaine Versus 10% Lignocaine Spray in Patients Undergoing Flexible Bronchoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Flexible bronchoscopy is common procedure used in the diagnosis and treatment of a variety of
      tracheobronchial diseases. During routine diagnostic flexible bronchoscopy, the most
      distressing symptom experienced by the patients is a cough, and control of a cough is vital
      for a successful procedure. The investigators hypothesized that either nebulized lignocaine
      or lignocaine spray given alone prior to flexible bronchoscopy for inducing topical
      anesthesia will have similar efficacy compared to the combination of the two agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Flexible bronchoscopy is common procedure used in the diagnosis and treatment of a variety of
      tracheobronchial diseases. The bronchoscope can be used to sample material not only from the
      visualized regions but also from the more distal pulmonary parenchyma. It is a safe
      outpatient exam that carries little risk. While performing the procedure most of the patients
      express some fear of pain, difficulty in breathing, nasopharyngeal irritation, and cough.
      During routine diagnostic flexible bronchoscopy, the most distressing symptom experienced by
      the patients is a cough, and control of a cough is vital for a successful procedure.
      Administration of a topical anaesthetic drug to the upper airway, larynx, and
      tracheobronchial tree can reduce a cough and patient's discomfort. The most commonly used
      topical anaesthetic agent in bronchoscopy is lignocaine because of its quick onset and short
      duration of action with decreased toxicity as compared to other agents. There are several
      ways to achieve topical anaesthesia in flexible bronchoscopy including nebulization, direct
      spray, by tracheal injection, or via nasal, or &quot;spray as you go&quot; technique through the
      working channel of the bronchoscope. The use of topical anaesthesia, sedation, and analgesia
      during flexible bronchoscopy varies according to physicians, institutions and geographic
      locations in the world. Generally, moderate sedation is used in bronchoscopy in which
      patients can respond to verbal commands. Deep sedation is less commonly used in which
      patients cannot be easily aroused but respond to repeated or painful stimulation.

      Antoniades et al. demonstrated that topical lidocaine through the bronchoscope significantly
      decreased cough frequency and the total dose of sedation required during flexible
      bronchoscopy. In a randomized controlled trial of 54 patients, Keane et al. concluded that
      nebulized and sprayed lignocaine have similar efficacy as topical anaesthetics in fiberoptic
      bronchoscopy but patients preferred the nebulized route. Noitasaeng et.al. concluded in their
      study that spraying lidocaine took less time to start the procedure, with greater ease of
      instrumentation, less incidence of hypersecretion, less gag reflex, and smooth operation
      during the procedure but patients preferred nebulized lidocaine administration.

      At the investigators' center, it has been a routine practice to perform flexible bronchoscopy
      without sedation in patients who require only diagnostic flexible bronchoscopy and assessment
      of airway anatomy and other routine procedures such as endobronchial biopsy or transbronchial
      biopsy. Previously, the investigators had shown that 1% lignocaine given by spray-as-you-go
      method was similar in efficacy to 2% lignocaine for topical anesthesia during routine
      flexible bronchoscopy. However, in this study both the groups received nebulized lignocaine
      and lignocaine spray prior to flexible bronchoscopy in addition to lignocaine solution ad
      lib.

      The investigators hypothesized that either nebulized lignocaine or lignocaine spray given
      alone prior to flexible bronchoscopy for inducing topical anesthesia will have similar
      efficacy compared to the combination of the two agents.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient-rated intensity of cough on a visual analog scale (VAS)</measure>
    <time_frame>One hour</time_frame>
    <description>The cough VAS is a 100-mm scale anchored by no cough on one end and worst cough on the other; the patient will indicate the severity of a cough by marking a line.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain assessment by the patient using the faces pain rating scale</measure>
    <time_frame>One hour</time_frame>
    <description>The Wong-Baker Faces Pain Scale combines the pictures and numbers to allow pain to be rated by the user. The faces range from smiling face to a sad, crying face. A numerical rating is assigned to each face, of which there is 6 total, where zero rating means no pain with smiling face and 10 mean worst pain with crying face</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-rated VAS of overall satisfaction of the procedure</measure>
    <time_frame>One hour</time_frame>
    <description>VAS on a 100-mm scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operator-rated intensity of cough on a VAS</measure>
    <time_frame>Immediately following the procedure</time_frame>
    <description>VAS on a 100-mm scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total lignocaine dose</measure>
    <time_frame>Immediately following the procedure</time_frame>
    <description>Total dose of lignocaine in milligrams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in respiratory rate following the procedure</measure>
    <time_frame>Baseline and 5 minutes after the procedure</time_frame>
    <description>Respiratory rate at baseline and 5 minutes after the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in heart rate following the procedure</measure>
    <time_frame>Baseline, during and 5 minutes after the procedure</time_frame>
    <description>Heart rate at baseline, during and 5 minutes after the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood pressure following the procedure</measure>
    <time_frame>Baseline and 5 minutes after the procedure</time_frame>
    <description>Blood pressure at baseline and 5 minutes after the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in oxygenation status following the procedure</measure>
    <time_frame>Baseline, during and 5 minutes after the procedure</time_frame>
    <description>Pulse oximetric saturation at baseline, during and 5 minutes after the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of procedure (in minutes)</measure>
    <time_frame>Immediately following the completion of flexible bronchoscopy</time_frame>
    <description>The total duration of bronchoscopy procedure in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Willingness of the patient to undergo the procedure yet again, if required</measure>
    <time_frame>One hour</time_frame>
    <description>Patient will indicate the willingness to undergo the procedure again, if required by a simple yes or no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions related to lignocaine</measure>
    <time_frame>One hour</time_frame>
    <description>Arrhythmia, involuntary movements, convulsions, anaphylaxis and bronchospasm</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Patients With Indication for Flexible Bronchoscopy</condition>
  <arm_group>
    <arm_group_label>Nebulized lignocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 ml of 4% lignocaine will be administered via nebulization prior to bronchoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lignocaine spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 puffs of 10% (10mg/puff) lignocaine spray will be sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined spray and nebulization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combination of 2.5 ml of 4% lignocaine via nebulization prior to bronchoscopy and 2 puffs of 10% (10mg/puff) lignocaine spray sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulized Lignocaine</intervention_name>
    <description>2.5 ml of 4% lignocaine will be administered via nebulization prior to bronchoscopy</description>
    <arm_group_label>Nebulized lignocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lignocaine spray</intervention_name>
    <description>10 puffs of 10% (10mg/puff) lignocaine spray will be sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy</description>
    <arm_group_label>Lignocaine spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combined spray and nebulization</intervention_name>
    <description>Combination of 2.5 ml of 4% lignocaine via nebulization prior to bronchoscopy and 2 puffs of 10% (10mg/puff) lignocaine spray sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy</description>
    <arm_group_label>Combined spray and nebulization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥18 years

          -  Willing for flexible bronchoscopy procedure a

        Exclusion Criteria:

          -  Requirement of intravenous sedation to undergo any procedure including EBUS-TBNA,
             conventional TBNA, radial EBUS procedure and interventional pulmonary procedures

          -  Sensitivity to lignocaine

          -  Hemodynamically unstable patients (SBP &lt; 90 mm Hg)

          -  Baseline hypoxemia (SpO2 &lt;92% on room air)

          -  Pregnancy

          -  Comorbid illness such as heart failure, CKD, chronic liver disease and others

          -  Failure to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ritesh Agarwal, MD, DM</last_name>
    <phone>0172-2756825</phone>
    <email>agarwal.ritesh@outlook.in</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Inderpau S Sehgal, MD, DM</last_name>
    <phone>0172-2756823</phone>
    <email>inderpgi@outlook.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bronchoscopy suite, PGIMER</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ritesh Agarwal, MD, DM</last_name>
      <phone>0172-2756825</phone>
      <email>riteshpgi@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ashutosh N Aggarwal, MD, DM</last_name>
      <phone>0172-2756824</phone>
      <email>dr.anaggarwal@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ritesh Agarwal, MD, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashutosh N Aggarwal, MD, DM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2017</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Postgraduate Institute of Medical Education and Research</investigator_affiliation>
    <investigator_full_name>Ritesh Agarwal</investigator_full_name>
    <investigator_title>Consultant, Department of Pulmonary Medicine, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

